Background
Acute myeloid leukemia (AML) is one of the most common hematologic malignancies with a poor prognosis and high recurrence rate. The discovery of new predictive models and therapeutic agents plays a crucial role.
Methods
The differentially expressed gene that was explicitly highly expressed in The Cancer Genome Atlas (TCGA) and GSE9476 transcriptome databases were screened and included in the least absolute shrinkage and selection operator (LASSO) regression model to derive risk coefficients and build a risk score model. Functional enrichment analysis was conducted on the screened hub genes to explore the potential mechanisms. Subsequently, critical genes were incorporated into a nomogram model based on risk scores to analyze prognostic value. Finally, this study combined network pharmacology to find potential natural compounds for hub genes and used molecular docking to verify the binding ability of molecular structures to natural compounds to explore drug development for possible efficacy in AML.
Results
A total of 33 highly expressed genes may be associated with poor prognosis of AML patients. After LASSO and multivariate Cox regression analysis of 33 critical genes, Rho-related BTB domain containing 2 (
RHOBTB2
), phospholipase A2 (
PLA2G4A
), interleukin-2 receptor-α (
IL2RA
), cysteine and glycine-rich protein 1 (
CSRP1
), and olfactomedin-like 2A (
OLFML2A
) were found to played a significant role in the prognosis of AML patients.
CSRP1
and
OLFML2A
were independent prognostic factors of AML. The predictive power of these 5 hub genes in combination with clinical features was better than clinical data alone in predicting AML in the column line graphs and had better predictive value at 1, 3, and 5 years. Finally, through network pharmacology and molecular docking, this study found that diosgenin in Guadi docked well with
PLA2G4A
, beta-sitosterol in Fangji docked well with
IL2RA
, and
OLFML2A
docked well with 3,4-di-O-caffeoylquinic acid in Beiliujinu.
Conclusions
The predictive model of
RHOBTB2
,
PLA2G4A
,
IL2RA
,
CSRP1
, and
OLFML2A
combined with clinical features can better guide the prognosis of AML. In addition, the stable docking of
PLA2G4A
,
IL2RA
, and
OLFML2A
with natural compounds may provide new options for treating AML.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.